SCHEMBL2946384

SCHEMBL2946384

COc1ccc2cc(-c3cnc(-c4cn(Cc5ccccc5)c5ccccc45)o3)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.44
CHRM1 P11229 2/20 0.42
HTR6 P50406 1/20 0.42
PLA2G2A P14555 2/20 0.41
F2RL3 Q96RI0 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2943810 0.87 THRA (0.44) SIRT2F2RL3CA12CA1CA2
SCHEMBL2945759 0.87 SIRT2 (0.39) SIRT2F2RL3CA12CA1CA2
SCHEMBL2944827 0.87 ENPP2 (0.48) SIRT2PLA2G2AF2RL3CA12CA1
SCHEMBL2944855 0.85 LMNA (0.41) CHRM1F2RL3ALDH1A1MAPTLMNA
SCHEMBL2951909 0.85 F2RL3 (0.42) SIRT2CHRM1PLA2G2AF2RL3CA12
SCHEMBL2945320 0.84 PPARG (0.46) F2RL3
SCHEMBL2948483 0.84 ALDH1A1 (0.46) ALDH1A1LMNAHPGDSMN1; SMN2CYP1A2
SCHEMBL2945245 0.83 PTPN1 (0.38) SIRT2HTR6F2RL3CA12CA1
SCHEMBL27925898 0.76 MAPT (0.56) SIRT2CHRM1F2RL3ALDH1A1MAPT
SCHEMBL2949331 0.76 TSHR (0.59) ALDH1A1MAPTLMNATP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754747-B2 Oxazolo-naphthyl acids WYETH LLC (US) 2010-07-13 US disclosed
EP-1781645-A1 OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES Wyeth (US) 2007-05-09 EP disclosed
US-20060052348-A1 Oxazolo-naphthyl acids WYETH (US) 2006-03-09 US disclosed
WO-2006023865-A1 OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES WYETH (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052348-A1 Oxazolo-naphthyl acids SERPINE1, SERPINB1, SERPINC1 SIRT2 1468/4885CHRM1 4613/4885HTR6 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.